Clinical Trial Update: JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 study of JAB-21822 in adults with KRAS G12C-mutant advanced solid tumors, including non-small cell lung cancer and colorectal cancer, has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• JAB-21822

Snippet

Sponsor: Jacobio Pharmaceuticals Co., Ltd. | Conditions: Advanced Solid Tumor, NSCLC | Phase 1, Phase 2 | Status: COMPLETED